A recent study from Leuven echoed these findings, noting that patients over 65 on anti-TNF therapy had a significantly higher risk of severe adverse events, with malignancy and infections more prevalent in this group (relative risk = 4.7; p < 0.001) 23. Here, TNF is linked to cancer.